NetScientific invests in PDS Biotechnology

15 December 2014

UK-based life sciences investor NetScientific (AIM: NSCI) has made an undisclosed investment in privately-held US biotech firm PDS Biotechnology Corp.

PDS is a clinical stage immunotherapy company developing a next-generation of simpler, safer and more effective immunotherapies for cancer and infectious disease. Its novel synthetic nanoparticle platform technology developed by PDS, Versamune, activates multiple immunological mechanisms which direct the targeting of cancer and infectious disease by the immune system.

The company’s lead product, PDS0101, is in Phase I clinical trials in the USA for HPV-related cancers. PDS has licensed the Versamune technology to Merck KGaA for use in two early stage cancer immunotherapy programmes. The company also has ongoing preclinical programs for other cancers as well as pandemic influenza.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK